# Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

> **NCT00057031** · PHASE2 · UNKNOWN · sponsor: **Novacea** · enrollment: 46 (—)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** DN-101 (calcitriol)

## Key facts

- **NCT ID:** NCT00057031
- **Lead sponsor:** Novacea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 46 (—)
- **Last updated:** 2006-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057031, "Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00057031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*